ABSTRACT There is as yet no convincing evidence that acetazolamide, a carbonic anhydrase inhibitor, is effective in obstructive sleep apnoea. A study was therefore designed to examine the effect of acetazolamide (250 mg/day) on sleep events and ventilatory control during wakefulness in nine patients with the sleep apnoea syndrome. In eight of the nine patients the apnoea index and the total duration ofapnoea were reduced by acetazolamide, and the mean (SEM) apnoea index of all patients changed from 25-0 (6 7) to 18 1 (5 8) episodes an hour. Furthermore, the total time of arterial oxygen desaturation (Sao2-more than 4% depression in Sao2 from the baseline sleeping level-divided by total sleep time was also significantly decreased and its mean (SEM) value improved from 24-1 (7 9) to 13-6 (4-8)% of total sleep time. Five 
This agent has been used successfully to improve periodic breathing during sleep at high altitude,56 and was also reported to be useful in central sleep apnoea. 7 On the other hand, Sharp et al8 observed that acetazolamide induced metabolic acidosis converted central to obstructive apnoea and worsened hypoxaemia in two patients with mixed apnoea. Shore et al9 reported a similar case. It remains to be determined therefore whether acetazolamide is useful or not for the treatment of sleep apnoea syndrome, and particularly for the subgroup with obstructive disease.
In the present investigation we have assessed the effect of acetazolamide in patients with sleep apnoea syndrome on indices of sleep disorder and ventilatory control during wakefulness.
Methods
Five men and four women patients with sleep apnoea syndrome were studied (table 1). In most of them polysomnography was performed because of their symptoms-for example, heavy snoring, excessive Conversion: SI to traditional units-Blood gas data: I kPa = 75 mm Hg.
daytime sleepiness, and insomniac sensation. The predominant apnoea was the obstructive type, which was present in eight obese patients; one patient (case 7) who had purely central apnoea accompanied by Cheyne-Stokes respiration was not obese. Patients 1 and 3 were mildly hypercapnic, and patients 1 and 4 had chronic obstructive pulmonary disease. Some of the patients were being treated with several drugs that continued to be administered throughout the study. At the time of the study all subjects were clinically stable. Before administering acetazolamide we performed polysomnography for two consecutive nights, studies of ventilatory control during wakefulness, pulmonary function tests, and arterial blood gas analysis. In the acetazolamide treatment run, 250 mg was given orally once a day and the tests were repeated on the seventh or eighth day of administration.
During the sleep studies surface electrodes were applied to obtain an electroencephalogram (EEG), an electrooculogram (EOG) and a submental electromyogram [EMG). Arterial oxygen saturation (Sao2) was measured continuously with an ear oximeter (Biox IIA). Movement of the chest wall and abdomen was measured with an inductance plethysmograph (Respitrace) and nasal flow with a thermistor. A polygraph was used to record all the variables.
Sleep stages were determined by the criteria of Rechtschaffen and Kales.'°Apnoea was defined as cessation of flow at the nose for at least 10 seconds. Central apnoea was thought to occur when respiratory effort and airflow were absent, and obstructive apnoea when respiratory effort continued without airflow. Hypopnoea was defined when airflow and respiratory movement were reduced in amplitude by one 14 Statistical analysis was performed by paired t test after confirmation that the variability within each group was the same.
Results

SYMPTOMS AND SIDE EFFECTS
Five of the seven patients who had varying degrees of daytime sleepiness, the four who felt difficulty in achieving full arousal on awakening, and three of the four who had an insomniac sensation had their symptoms improved to some degree during acetazolamide administration. Though two patients complained of dysaesthesia of the extremities and Tojima, Kunitomo, Kimura, Tatsumi, Kuriyama, Honda Conversion: SI to traditional units-Blood gas data: I kPa = 75 mm Hg; occlusion pressure (P0-2) data: I kPa = 10 2 cm H20.
another complained of pollakiuria, all patients able to ventilatory response line shifted to a lower Pco2 range. continue taking the drug. than 4% depression in Sao2 from the baseline sleeping level) divided by total sleep time. The baseline and the lowest Sao2 in REM sleep showed a tendency to increase, but these changes were not significant. The lowest Sao2 in non-REM sleep, however, increased significantly. Furthermore, the percentage of total desaturation time decreased significantly. This value in the nine patients had varied from 1-0% to 69-2% (mean 24 1%) during the control period, and the improved values were 01-42 1% (mean 13.6%) during acetazolamide administration. The apnoea index and apnoea time became worse in case 8. This patient, however, had a diminished desaturation time owing to a considerable reduction in hypopnoeic episodes. On the other hand, in case 6, although the apnoea index decreased, the desaturation time did not change owing to the increase in episodes of hypopnoea. This patient showed a fluttering pattern in the expiratory limb ofthe flow-volume loop that may have reflected the upper airway obstruction he had while awake." but central and mixed types of apnoea were also observed to some extent. In no case was the type of apnoea that predominated induced by acetazolamide. The changes in the apnoea index, total apnoea time/ total sleep time, and desaturation time/total sleep time were not significantly related to changes in the ventilatory and occlusion pressure responses to carbon dioxide during wakefulness. Moreover, they were not correlated with changes in Paco2 and Pao2
Discussion
We found in this study that acetazolamide reduced but did not remove the episodes of obstructive apnoea and oxygen desaturation during sleep and that it ameliorated clinical symptoms associated with disordered breathing. Acetazolamide has been shown to be effective in two sorts of sleep disordered breathing. Firstly, during acute high altitude exposure acetazolamide was reported to reduce the number of episodes of periodic breathing and improve arterial oxygen saturation.56 Acetazolamide is known to be useful for the prevention of acute mountain sickness.'6 Secondly, White and colleagues7 reported that acetazolamide substantially reduced episodes of central apnoea in all their six patients. Findley et al '7 noted that acetazolamide calmed down the oscillations of ventilatory movement and abolished the recurrent episodes of apnoea in Cheyne-Stokes breathing. In contrast, Sharp and colleagues8 showed that metabolic acidosis produced by acetazolamide converted central apnoea to obstructive or mixed apnoea. The reason for this remains uncertain, but it may very well be due to the generation of greater negative inspiratory pressure, facilitating upper airway closure. No further reports, however, have appeared to substantiate the evidence of either beneficial or adverse effects of acetazolamide on obstructive sleep apnoea.
The number of apnoeic episodes per hour of total sleep time during the control period varied from 5 4 to 571; in two mild cases it was less than 10. The conventional definition for sleep apnoea syndromemore than five apnoeic episodes an hour-may in fact be an inappropriately small index number for predicting increased health risk or somnolence in subjects over 60 years of age.'8 The two patients with the mild syndrome, however, were a 33 year old man and a 58 year old woman. We therefore diagnosed them as having sleep apnoea syndrome. The mean apnoea index of our subjects was 25 0, indicating a relatively mild sleep apnoea syndrome. The one patient with severe obstructive apnoea treated with acetazolamide but failing to show improvement in oxygen desaturation had the so called "saw tooth" configuration in her expiratory flow-volume curve."' In cases where obstructing lesion or abnormality is present in the upper airway it may be difficult to improve the disordered breathing.
In our study one During acetazolamide treatment comparison of the hypoxic ventilatory response with the control response was difficult because Pco2 was depressed by the drug administration. Whether there is an interactive effect between metabolic acidosis and hypoxic chemosensitivity remains to be determined,2627 but our previous study23 and that of Powles et al8 indicated that acetazolamide did not enhance the hypoxic ventilatory response in eucapnic conditions. Another possible mechanism for reducing episodes of apnoea by acetazolamide is alteration of the distribution profile of sleep stages, as was seen after protriptyline.2 In our results, however, there was no remarkable change in sleep stages, and acetazolamide reduced sleep apnoea similarly in both non-REM and REM sleep, except in one patient, whose apnoea index increased only in non-REM sleep. A significant increase in lowest Sao2 was seen in non-REM sleep, whereas a significant improvement in apnoea index was observed in each sleep stage. From these findings it is difficult to believe that acetazolamide had different effects on non-REM and on REM sleep.
To evaluate the effect of a chemical agent on sleep disordered breathing in patients with sleep apnoea syndrome, quantitative measurement appears to be as important for hypopnoeic episodes as for apnoea. In fact, in our study there was one patient whose apnoeic episodes were diminished but hypopnoeic episodes were increased, so that the total desaturation time was not improved. Oxygen desaturation time depends on lung volume (functional residual capacity), baseline Sao2, and the number and duration of episodes of apnoea and hypopnoea. Thus the beneficial effects of acetazolamide on sleep apnoea syndrome seem to be reflected by the reduction of desaturation time.
On the other hand, care must be taken regarding the negative effects of acetazolamide. Since it is known that metabolic acidosis affects pulmonary arterial resistance, cardiac contractility, and oxygen transport, this drug should be used only in conjunction with careful control of arterial pH. We used only 250 
